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Abstract 
Cellular senescence is a state of irreversible cell cycle arrest in response to non-lethal 
stress. In cancer cells, senescence can be induced by chemotherapy, radiation, or signals from the 
tumor microenvironment, such as transforming growth factor β (TGFβ). Senescent cells are 
metabolically active and have altered gene expression compared to their non-senescent 
counterparts. Senescent cells release a wide variety of factors, including extracellular domains of 
transmembrane proteins that require proteolytic cleavage by specific proteases. ADAMs (A 
Disintegrin and Metalloprotease domain-containing proteins) are enzymes that cleave many 
transmembrane proteins, such as growth factor precursors or adhesion molecules, and thus may 
act as sheddases in senescent cells. Here, we investigate ADAM expression levels during TGFβ- 
induced cellular senescence.    
SUM149PT and SUM102PT breast cancer cells were incubated with TGFβ, followed by 
treatment with high doses of paclitaxel to remove actively proliferating, non-senescent cells. 
Induction of cellular senescence was examined by evaluating changes in cell size and 
granularity, and by β-galactosidase staining. ADAM mRNA levels were measured by quantitative 
reverse transcription polymerase chain reaction (qRT-PCR). Among several ADAMs tested, 
ADAM12 mRNA was significantly upregulated in senescent cells. In addition, we demonstrated 
that ADAM12 knock-down leads to decreased activation of epidermal growth factor receptor 
(EGFR), an important modulator of cancer cell growth, survival, and metastasis. This effect of 
ADAM12 knock-down was likely due to a diminished release of soluble EGF or EGF-like 
ligands from cells. Since senescent cells often release increased amounts of these ligands, 
ADAM12 may modulate the senescence secretome in senescent breast cancer cells. 
 
 
iv 
Table of Contents 
 
List of Figures ................................................................................................................................ vi	
List of Tables ................................................................................................................................ vii	
List of Abbreviations ................................................................................................................... viii	
Acknowledgments ........................................................................................................................... x	
Chapter 1 - Literature Review ......................................................................................................... 1 
Cellular Senescence .................................................................................................................... 1 
Causes of Cellular Senescence ................................................................................................ 1 
Induction of Cellular Senescence by TGFβ ........................................................................ 2	
Hallmarks of Cellular Senescence .......................................................................................... 3	
Different Roles of Cellular Senescence .................................................................................. 5	
Regulation of SASP ................................................................................................................ 7	
The ADAM Metalloproteases ..................................................................................................... 8 
Patterns of ADAMs Expression ............................................................................................ 10 
Hematopoietic ADAMs .................................................................................................... 10	
Globally Expressed ADAMs ............................................................................................ 11	
EGFR Signaling ........................................................................................................................ 15 
References ................................................................................................................................. 21	
Chapter 2 - Expression of ADAM Metalloproteases during Transforming Growth Factor β- 
Induced Senescence in Breast Cancer Cells ................................................................................. 33 
Abstract ..................................................................................................................................... 33	
Introduction ............................................................................................................................... 34	
Materials and Methods .............................................................................................................. 36	
    Results ....................................................................................................................................... 39 
TGFβ-induced senescence in breast cancer cell lines ........................................................... 39	
Survey of ADAM expression in senescent cells  ................................................................... 40 
Cell surface expression of ADAM12 in senescent cells ....................................................... 41	
Discussion ................................................................................................................................. 41	
References ................................................................................................................................. 52 
Chapter 3 - ADAM12 Activates EGFR Signaling through the Cleavage of EGFR Ligands ....... 55 
v 
Abstract ..................................................................................................................................... 55	
Introduction ............................................................................................................................... 56	
Materials and Methods .............................................................................................................. 57	
    Results ....................................................................................................................................... 60 
The basal activation of EGFR is mediated by endogenously expressed ligands in 
SUM159PT cells ................................................................................................................... 60	
ADAM12 knock-down does not change EGFR responsiveness to EGF .............................. 60	
Discussion ................................................................................................................................. 61	
References ................................................................................................................................. 67 
Chapter 4 - Final Conclusions ....................................................................................................... 70 
References ................................................................................................................................. 73 
Appendix A - Copyright permissions ........................................................................................... 75	
vi 
 
List of Figures 
 
Figure 1.1 TGFβ signaling pathways are mediated either through Smad-dependent or Smad-
independent pathways ........................................................................................................... 17 
Figure 1.2 Different signaling pathways can regulate NF-κB ...................................................... 18 
Figure 1.3 Domain organizations of ADAM metalloproteases .................................................... 20 
Figure 2.1 Small populations of cells are resistant to high doses of paclitaxel after TGFβ 
       treatment in SUM102PT and SUM149PT cell lines .............................................................. 45 
Figure 2.2 TGFβ treatment induces cellular senescence in SUM102PT ...................................... 47 
Figure 2.3 Survey of ADAM expression in senescent SUM102PT cells ...................................... 48 
Figure 2.4 Survey of ADAM expression in senescent SUM149PT cells ...................................... 49 
Figure 2.5 ADAM12 protein expression at the cell surface upon induction of senescence in 
SUM102PT cells ................................................................................................................... 50 
Figure 3.1 The basal activation of EGFR in SUM159PT cells is mediated by endogenously 
expressed ligands .................................................................................................................. 64	
Figure 3.2 ADAM12 knock-down decreases the basal activation of EGFR ................................ 65 
Figure 3.3 ADAM12 does not alter the EGFR responsiveness to EGF ........................................ 66 
 
 
 
 
 
 
 
 
 
 
vii 
List of Tables 
 
 
Table 2.1 Primer sequences. ......................................................................................................... 36	
	
 
viii 
 
List of Abbreviation 
ADAMs                      A Disintegrin and Metalloproteases  
CCN1/CYR61            CYR61, CTGF, NOV/Cysteine-rich angiogenic inducer 61  
DDR                           DNA damage response 
DLL1                         Delta-like 1 
DNA-SCARS            DNA segments with chromatin alteration reinforcing senescence  
ECM                          Extracellular matrix  
EGF                           Epidermal growth factor 
EGFR                        Epidermal growth factor receptor 
EMT                          Epithelial-to-mesenchymal transition  
FSC                           Forward scatter 
HB-EGF                    Heparin-binding EGF-like growth factor 
ICAM-1                     Intercellular adhesion molecule  
IGFBP                        Insulin-like growth factor binding protein 
IκB                             Inhibitory kappa B  
MEF                           Mouse embryonic fibroblasts   
NF-κB                        Nuclear factor kappa B 
NGF                           Nerve growth factor  
ix 
OPG                           Osteoprotegrin  
pRb                    Phosphorylated retinoblastoma 
PRS                           Proline-rich sequence  
PTX                          Paclitaxel  
qRT-PCR                 Quantitative reverse transcription polymerase chain reaction 
SA-β-gal                  Senescence-associated-β-galactosidase   
SAHF                      Senescence associated heterochromatin foci 
SASP                      Senescence associated secretory phenotype 
SH3                           Src homology 3  
SSC                         Side scatter  
TGFα                     Transforming growth factor α  
TGFβ                    Transforming growth factor β  
TNFα                    Tumor necrosis factor α 
TNFR1                  Tumor necrosis factor receptor 1 
TRAF6                      TNF receptor associated factor 6  
VEGF                       Vascular endothelial growth factor 
 
 
 
x 
Acknowledgements 
At the beginning, I would like to thank my major professor Dr. Anna Zolkiewska for her 
support, patience, and encouragement during my study here at Kansas State University. Also, I 
would like to thank Dr. Michal Zolkiewski, Dr. Stella Lee, and Dr. Timothy Durrett for serving 
as my committee members. 
In addition, I would like to thank Randi Wise. She was a lab mate, friend, and sister for 
me here in USA. She helped each time I was in need. 
Last but not least, I would like to thank my wonderful husband, Dr. Mohammed Obeidat 
for his love, support and patience. You always believed in my abilities and encouraged me in 
each single step in my life.     
 
 
 
 
1 
Chapter 1 - Literature Review 
Cellular Senescence  
 
Cellular senescence is a physiological process that can be induced either by intrinsic or 
extrinsic factors, such as telomere shortening, signals from the tumor microenvironment, or 
genomic and epigenomic damage (Sabin & Anderson 2011). Senescence was first described in 
1965 as a process that limits cell proliferation. The main feature of senescent cells is that they are 
irreversibly arrested to prevent the transmission of a cellular damage to daughter cells (Sabin & 
Anderson 2011). Therefore, senescence is closely linked to aging and tumor suppression (Rodier 
& Campisi 2011). 
 
Causes of Cellular Senescence  
There are many inducers of cellular senescence, such as telomere shortening, signals 
from the tumor microenvironment, transforming growth factor β (TGFβ), genomic and 
epigenomic damage, or activation of tumor suppressors using strong mitogenic signals, which is 
called oncogene induced senescence (OIS) (Campisi 2014; Salminen 2012).  
Telomere shortening in eukaryotes is one of the best known mechanisms for induction of 
cellular senescence. With each cell division, telomeres, which are repetitive DNA sequence that 
are found at the end of each chromosome, are shortened. This prevents the complete replication 
of the DNA. As a result, after several cell divisions, the shortening of the telomeres activates the 
DNA damage response (DDR), which leads to the activation of p53, a tumor suppressor, and 
growth arrest due to the induction of senescence (Campisi 2014; Fumagalli 2012).  
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Genomic damage is another way to induce cellular senescence. Ionizing radiation, 
cytotoxic chemotherapeutic agents, oxidative stress, or other DNA damaging agents can result in 
genomic damage. These factors produce persistent DDR signaling that leads to the induction of 
cellular senescence (Salminen 2012; Campisi 2014).  
OIS results from applying strong mitogenic signals for an extended period of time on 
cells. One of the best-known mitogenic signals is the oncogenic protein RasV12. Serrano et al. 
showed that the expression of RasV12 in human and rodent fibroblasts induces senescent growth 
arrest as a result of activation of p53 and p16, a cell cycle inhibitor (Serrano 1997). The 
BRAFE600 oncogene is another example of a mitogenic signal whose overexpression in 
fibroblasts induced cellular senescence (Kuilman 2008). The induction of senescence in response 
to specific mitogenic stimuli is a mechanism for tumor suppression, which might explain an 
apparent need to mutate the genes involved in OIS, such as p53 during tumor progression 
(Serrano 1997).   
The focus of the following section will be on TGFβ, which is the agent used in this study 
to induce cellular senescence.  
 
Induction of Senescence by TGFβ 
     TGFβ is a member of the cytokine family that has important implications in cell 
proliferation, differentiation, and apoptosis (Mu 2012). TGFβ mediates cellular processes via 
canonical, Smad-dependent, or non-canonical, Smad-independent pathways. In the Smad-
dependent pathway, TGFβ binds to TGFβR2, which recruits and phosphorylates TGFβR1. Then, 
TGFβR1 phosphorylates R-Smads that bind to Smad4 and translocate into the nucleus. In the 
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nucleus, R-Smad/Smad4 complexes act as transcription factors to regulate the expression of 
various target genes (Mu 2012).  
Multiple Smad-independent pathways have been identified; one of the examples of those 
pathways is the TGFβ-TAK1-NF-κB pathway. This pathway can also modulate the induction of 
cellular senescence (see The SASP Regulation section) (Figure 1.1). It has been shown that 
TGFβ induces growth arrest and cellular senescence in different cells, such as hepatocellular 
carcinoma cells (Senturk 2010), mouse embryonic fibroblast (MEF) (Pérez-Rivero 2008), or 
mouse keratinocytes (Vijayachandra 2009). Moreover, many reports showed that TGFβ induces 
the expression of different cell cycle inhibitors, such as p15, p21, p57, or p16, which leads to 
growth arrest (Senturk 2010; Vijayachandra 2009). Finally, TGFβ and its receptors were induced 
by the oxidative stressor H2O2 in human fibroblasts, which led to the induction of cellular 
senescence (Dumont 2001).  
 
Hallmarks of Cellular Senescence  
     Senescent cells have many characteristics, such as irreversible growth arrest and 
increased β-galactosidase enzyme activity; however, no single marker is exclusive to senescent 
cells. Moreover, it is not necessary for senescent cells to express all known features of 
senescence. Senescent cells should express a group of markers that collectively define their state 
(Rodier & Campisi 2011; Campisi 2014; Ohtani & Hara 2013). 
The following are some of the main features of senescent cells: 
1) Unlike cells in a quiescent state, which is a state of reversible cell cycle arrest, senescent 
cells undergo a permanent, irreversible growth arrest. This means that even if a growth 
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stimulus is provided to senescent cells, the cells will not re-enter the cell cycle (Rodier & 
Campisi 2011; Campisi 2014; Sabin & Anderson 2011). 
2) Senescent cells undergo various morphological changes; along with being approximately 
two-fold larger than their non-senescent counterparts, senescent cells also have a 
flattened morphology under tissue culture conditions (Rodier & Campisi 2011; Sabin & 
Anderson 2011; Campisi 2014). 
3) Senescent cells are characterized by increased activity and expression of the lysosomal 
senescence-associated-β-galactosidase (SA-β-gal) enzyme, which is detectable at near-
neutral pH (Rodier & Campisi 2011; Campisi 2014). 
4) Senescent cells have an increase in the expression of one or more of the following cell 
cycle regulatory proteins: p16, p19, p21, or p53 (Rodier & Campisi 2011; Campisi 2014; 
Sabin & Anderson 2011).  
5) Senescent cells have different types of nuclear foci, such as DNA segments with 
chromatin alteration reinforcing senescence (DNA-SCARS), which are sites that contain 
different DDR proteins. Senescence associated heterochromatin foci (SAHF) are other 
examples of foci found in senescent cells. SAHF are formed as a result of p16 activation. 
This type of foci contain silenced pro-proliferative genes (Campisi 2014; Rodier & 
Campisi 2011). 
6) Senescent cells produce and secrete different factors such as cytokines, chemokines, and 
matrix remodeling factors. Collectively, this phenotype is called senescence associated 
secretory phenotype (SASP). The effects and the identities of SASP vary, depending on 
the cell type and the method of induction of senescence. SASP is a feature that potentially 
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could explain the role of senescent cells in aging and several pathological conditions like 
cancer (Rodier & Campisi 2011; Campisi 2014).  
 
SASP components can be divided into three groups:  
1) Soluble factors. This group includes interleukins, such as IL-6, 7 and 13, various 
chemokines, such as eotaxin, and growth factors, such as NGF, and many others.  
2) Shed receptors or ligands, which include ICAM-1 and EGF. These factors need specific 
sheddases in order to be cleaved and released from the cell surface of senescent cells.  
3) Insoluble factors, which include fibronectin, collagens, and laminin.  
Collectively, SASP factors can affect the surrounding cells by acting on specific cell-
surface receptors, resulting in the activation or inhibition of different signaling pathways. 
Changes in the activities of these pathways may lead to different pathological conditions, such as 
cancer (Coppé 2010).  
 
Different Roles of Cellular Senescence  
Cellular senescence plays an important role in different processes, including wound 
healing, tissue repair, tumor suppression, and tumor progression (Rodier & Campisi 2011; Sabin 
& Anderson 2011).  
In cutaneous wound healing, the matricellular protein CCN1/CYR61, which is a highly 
expressed at the sites of tissue repair, induces cellular senescence in fibroblasts.  CCN1/CYR61 
increases the accumulation of reactive oxygen species (ROS), resulting in the induction of DNA 
damage response and activation of the p53 tumor suppressor gene (Jun & Lau 2010). Activation 
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of DNA damage response and p53 in turn leads to the activation of the p16INK4a cell cycle 
inhibitor and causes fibroblasts to become senescent. Senescent fibroblasts express antifibrotic 
genes that limit fibrosis during the wound healing process (Jun & Lau 2010; Sabin & Anderson 
2011). Similarly, it has been found that senescent cells that are derived from activated hepatic 
stellate cells produce matrix metalloproteinases to resolve fibrosis resulting from the production 
of the extracellular matrix during liver injury (Krizhanovsky 2008).  
In cancer, cellular senescence has long been considered a mechanism of tumor 
suppression for several reasons. First, senescent cells undergo growth arrest, whereas tumor cells 
are highly proliferative, which is one of the hallmarks of cancer (Siddiqa & Marciniak 2008). 
Second, senescent cells are activated via two important tumor suppressor pathways, the tumor 
suppressor p53 pathway and the pRB/p16 pathway (Campisi & d’Adda di Fagagna 2007; Chen 
2005; Rodier 2007). These pathways are highly mutated in most cancers in human and mice 
(Rodier & Campisi 2011). Moreover, some of the SASP components have been shown to 
maintain the senescence state. For example, secretion of the proinflammatory cytokines IL-6 and 
IL-8 is increased upon induction of senescence by the BRAFE600 oncogene. This increase in IL-6 
and IL-8 maintains the senescent state. Furthermore, knocking-down IL-8 reduces the number of 
senescent cells (Acosta 2008; Kuilman 2008).  
In contrast, cellular senescence can be also considered a driving force for cancer, mainly 
due to the function of different SASP components. For example, MMP3, also called stromelysin, 
and amphiregulin, which are SASP components, are able to stimulate the tumor cell growth 
(Bavik 2006; Liu & Hornsby 2007). Liu et al. showed that when senescent fibroblasts were co-
transplanted with cancer cells into immunocompromised mice, the proliferation of cancer cells 
was increased (Liu & Hornsby 2007). Moreover, it has been shown that different SASP 
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components induce the Epithelial-to-Mesenchymal transition (EMT), a critical process in 
metastatic tumors (Laberge 2012). Finally, it is known that senescent cells secrete factors that 
increase the resistance of non-senescent cells to specific chemotherapeutic agents, such as 
doxorubicin (Gilbert & Hemann 2010). 
 
 Regulation of SASP 
Several positive and negative regulators of SASP have been identified. Among those 
regulators, nuclear factor kappa B (NF-κB) is the major inducer of SASP components (Salminen 
2012; Rovillain 2011). NF-κB is a transcription factor, which in its inactive state is found in the 
cytoplasm and interacts with inhibitory kappa B (IκB) protein. Upon activation, IκB is 
phosphorylated, poly-ubiquitinated and degraded, which allows NF-κB to translocate to the 
nucleus, dimerize, and regulate the expression of several genes, such as IL-1, 6, and 8, cell 
adhesion molecules, and different cell cycle regulators. NF-κB has been implicated in different 
pathological conditions including diabetes, atherosclerosis, asthma, and cancer, as well as other 
biological processes, such as the adaptive and innate immunity (Salminen  2012; Serasanambati 
& Chilakapati 2016; Sun 2004). 
Chien et al. showed that p65, an NF-κB subunit, was enriched in the chromatin of 
senescent cells. Moreover, Rouvillain et al. showed that the inhibition of NF-κB could overcome 
senescence induced by p53/p21 signaling in immortalized human fibroblasts (Rovillain 2011). 
This agrees with results of another study, in which it was shown that the suppression of NF-κB 
in a mouse lymphoma model prevented the induction of cellular senescence upon treatment with 
etoposide, a chemotherapeutic drug (Chien 2011).  
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Different potential signaling pathways were identified to regulate NF-κB (Figure 1.2). It 
has been shown that TGFβ receptor activates TGFβ-activated kinase 1 (TAK1), which leads to 
the activation of IκB kinase. IκB kinase phosphorylates IκB, which results in its poly-
ubiquitination and degradation by the 26S proteasome. As mentioned previously, this allows to 
NF-κB to translocate into the nucleus and activate the transcription of different genes 
(Serasanambati & Chilakapati 2016; Sun 2004).  
   
The ADAM Metalloproteases 
 A Disintegrin and Metalloprotease-containing proteins (ADAMs) are a family of 
membrane-anchored proteases (Giebeler & Zigrino 2016). ADAMs regulate important cellular 
processes, such as cell adhesion, migration, and differentiation. ADAMs are mainly involved in 
the proteolytic ectodomain release or shedding of various transmembrane proteins, such as 
growth factors, cytokines, different receptors, or cell adhesion molecules (Reiss & Saftig 2009). 
 In the human genome, twenty-two ADAMs have been described. Among them, twelve 
genes encode proteins that express a typical metalloprotease Zn-binding active site; those are 
ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, and 33 (Jones, Rustagi, & Dempsey 2016). 
ADAMs are multidomain transmembrane proteins. The domain structure includes a prodomain, 
a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a 
transmembrane domain, and a cytoplasmic domain (Figure 1.3). In addition to ADAM domains, 
ADAMs have an N-terminal signal sequence that directs them into the secretory pathway as type 
1 transmembrane proteins (Weber & Saftig 2012). The signal sequence is removed in the 
endoplasmic reticulum, then ADAMs are folded, glycosylated, and trafficked to the Golgi 
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apparatus. In the trans-Golgi network, ADAMs are activated by cleaving off their prodomain via 
pro-protein convertases. Finally, the mature, active form of an ADAM protein is usually 
trafficked to the cell surface (Gomis-Ruth 2009; Wong 2015). 
 The prodomain, which is located at the N-terminal portion of ADAMs, has two 
functions; first, it serves as an autoinhibitory domain of the catalytic metalloprotease domain, 
and second, it acts as an intramolecular chaperone to assure the correct folding of the ADAM 
protein (Wong 2015).  
Downstream of the prodomain, there is a metalloprotease domain that contains the 
catalytic HEXGHXXHD motif. The three histidine residues bind with a zinc atom and form the 
catalytic center (Jones, Rustagi, & Dempsey 2016; Gomis-Ruth 2009). Since several ADAMs 
(ADAM18, ADAM22, ADAM23, ADAM29, and ADAM32) are catalytically inactive, it has 
been suggested that ADAMs might also function in protein-protein interaction.  
Downstream of the disintegrin domain, there is a cysteine-rich domain, which plays a 
role in protein-protein interactions and determines the substrate specificity (Jones, Rustagi, & 
Dempsey 2016). It has been suggested that this domain is important in regulating the catalytic 
activity of ADAMs. Takeda et al. crystalized the vascular apoptosis-inducing factor-1, which is a 
snake venom toxin that contains Metalloproteinase/Disintegrin/Cysteine-rich (MDC) domains 
similar to those present in ADAMs (Takeda 2006). The results showed that the cysteine-rich 
domain faces the metalloprotease domain at ~4 nm, which suggests that this domain may capture 
specific substrates in order to be processed by the metalloprotease domain (Takeda 2006). The 
EGF-like domain may mediate multimerization of ADAM17 (Lorenzen 2011). The cytoplasmic 
domain contains one or more proline-rich sequence (PRS), which potentially enables the 
interaction with Src homology 3 (SH3) domain that is found in many signaling molecules. For 
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example, ADAM10 has two PRSs (Lettau 2014), ADAM12 contains multiple SH3 binding 
motifs which are known to interact with Src kinases and the p85α subunit of phosphatidylinositol 
3 kinase (PI3K) (Li 2013; Kang 2001).  
 
Patterns of ADAMs Expression 
In general, ADAMs are expressed at different levels in different tissues. For example, 
approximately one third of human ADAMs, including ADAM2, 7, 18, 20, 21, 29, 30, are 
expressed in the testis and/or its associated structures (Cho Chughee 2012; Edwards 2009; Seals 
& Courtneidge 2003). In the following sections, the other two groups of ADAMs, hematopoietic 
and globally expressed ADAMs, will be reviewed. Only the catalytically active ADAMs will be 
discussed in each group.  
 
Hematopoietic ADAMs 
The hematopoietic ADAMs include ADAM8 and ADAM28 (Edwards 2009). These two 
ADAMs are catalytically active and able to autocleave their respective prodomains (Romagnoli 
2014; Edwards 2009). In other words, they do not need pro-protein convertases to cleave their 
prodomain in order to become active. 
ADAM8, also called CD156a, is expressed mainly in immune cells, such as granulocytes, 
monocytes, myeloid cells and neutrophils (Yeh & Klesius 2009; Romagnoli 2014). In 
neutrophils, ADAM8 is activated and participates in the neutrophil inflammatory response (Yeh 
& Klesius 2009). ADAM8 has been also implicated in different pathological conditions, such as 
allergy and brain, prostate, and lung cancers (Yeh & Klesius 2009; Romagnoli 2014). ADAM8 
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can cleave different transmembrane proteins, such as L-Selectin, a cell adhesion protein 
expressed in neutrophils (Gomez-Gaviro 2007; Fourie 2003). However, despite of the link 
between ADAM8 and various ailments, a mouse knock-out of ADAM8 is viable and has no 
pathological phenotype (Kelly 2005).  
ADAM28, which is also known as the lymphocyte metalloprotease MDC-L, is mainly 
expressed in lymphocytes, monocytes, and neutrophils; however, it is also expressed in the lung, 
spleen, and epididymis (Bridges 2002; Nuttall 2004). Moreover, Mitsui et al. showed that 
ADAM28 is overexpressed in human breast cancer cells and its expression increases the 
proliferation of cells (Mitsui 2006). ADAM28 has different functions; for example, it has been 
shown that the disintegrin domain of ADAM28 interacts with α4β1 integrin that is found in 
leukocytes. This raises a possibility that ADAM28 plays a role in lymphocyte-leukocyte 
interactions (Bridges 2002). Also, ADAM28 cleaves insulin-like growth factor binding protein-3 
(IGFBP-3) into two major fragments. The cleavage of IGFBP-3 results in releasing of IGF-I 
from the IGF-I/IGFBP-3 complex, which leads to increase in proliferation of the breast 
carcinoma cells (Fourie 2003; Mochizuki 2004; Mitsui 2006). 
 
Globally Expressed ADAMs 
This group contains the largest number and the most diverse ADAMs. Catalytically 
active ADAMs from this group include ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, 
ADAM19, and ADAM33. Catalytically inactive, globally expressed ADAMs, like ADAM11, 
ADAM22, ADAM23, and ADAM32, will not be discussed in this review. 
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ADAM9 expression is increased in different pathological conditions such as breast, 
prostate and intestinal cancers (Edwards 2009). ADAM9 knock-out mice do not exhibit a defect 
in the growth or development (Sahin 2004). ADAM9 cleaves different transmembrane proteins, 
for example, pro-EGF and pro-HB-EGF (Reiss & Saftig 2009; Izumi 1998; Mohan 2002). 
ADAM10 has been extensively studied because of its broad substrate specificity. Moreover, 
knock-out of the ADAM10 gene in mice showed embryonic lethality as a result of cardiovascular 
and central nervous system defects (Hartmann 2002). ADAM10 is mainly expressed in stem 
cells, placenta, bladder, and blood myeloid cells (Edwards 2009). Also, ADAM10 is upregulated 
in prostate cancer and it has an important role in Alzheimer’s disease (Edwards 2009). Chen et 
al. showed that ADAM10 and ADAM17 shed the anti-aging transmembrane protein klotho in 
COS-7 cells and rat kidney; cotransfection of klotho with ADAM10 or ADAM17 small 
interference RNA decreased the secretion of klotho (Chen 2007). Furthermore, ADAM10 
cleaves a variety of substrates such as EGF, E-cadherin, and IL-6 receptor (Reiss & Saftig 2009). 
ADAM12 is mainly expressed in stem cells and the placenta during pregnancy (Edwards  
2009). ADAM12 knock-out mice studies showed 30 % embryonic lethality and abnormalities in 
the brown fat tissues (Kurisaki 2003). ADAM12 was shown to be upregulated in breast and 
bladder cancer (Lendeckel 2005; Narita 2012). It has been shown that the overexpression of 
ADAM12 in breast cancer cells and in a mouse model of breast cancer, mouse mammary tumor 
virus-polyoma middle T antigen (MMTV-PyMT), promoted tumor growth. In a complementary 
approach, knock-down of ADAM12 in the same MMTV-PyMT mouse model reduced tumor 
progression (Roy 2011; Fröhlich 2011). Those data suggest that ADAM12 is an important 
modulator of breast cancer progression.  
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ADAM12 cleaves many transmembrane proteins (Edwards 2009). Asakura et al. showed 
that ADAM12 increases the secretion of HB-EGF in cardiomyocytes (Asakura 2002). Delta-like 
1 ligand (DLL1) is another protein that is cleaved by ADAM12, and other ADAMs, such as 
ADAM9 and ADAM17 (Edwards 2009; Dyczynska 2007). DLL1, which is an integral 
membrane protein, interacts with Notch receptor on the neighboring cells in a trans manner, and 
as a result, the Notch signaling pathway is activated (Kopan 2012). The Notch signaling pathway 
is conserved between species and it plays a key role in cell proliferation, differentiation, and 
death (Kopan 2012). The cleavage of DLL1 via ADAMs inhibits Notch signaling since the 
ligand becomes less available at the cell surface to interact in trans with Notch receptor. 
Moreover, it has been shown that ADAM12 degrades different extracellular matrix (ECM) 
proteins, such as gelatin, type IV collagen, and fibronectin, which suggests that ADAM12 might 
have an important role in ECM remodeling (Roy 2004). 
ADAM15 and ADAM19 are expressed in a wide range of tissues (Edwards 2009). 
ADAM15 knock-out mice showed normal development, however, these mice developed 
osteoarthritis later in life (Böhm 2005). ADAM19 knock-out mice showed 80% lethality due to 
cardiovascular defects (Reiss & Saftig 2009). ADAM15 cleaves different transmembrane 
proteins, including CD23, HB-EGF, and E-cadherin (Reiss & Saftig 2009). ADAM19 cleaves 
other transmembrane proteins, for example, neuregulin β1 in the Golgi apparatus of sensory 
neurons (Yokozeki 2007). 
Similar to ADAM10, ADAM17 is an extensively studied ADAM, since it acts upon a 
wide variety of substrates (Edwards 2009). Knock-out of the ADAM17 gene in mice is lethal due 
to heart defects (Jackson 2003; Edwards 2009). ADAM17 is expressed in many tissues, with the 
highest expression being observed in the lymphatic system (Edwards 2009; Reiss & Saftig 
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2009). Moreover, ADAM17 is upregulated under many pathological conditions, such as 
rheumatoid arthritis, multiple sclerosis, diabetes, and breast cancer (Edwards 2009). ADAM17 
overexpression in breast cancer cell lines increased cell proliferation, invasion, and tube 
formation. Downregulation of ADAM17 expression by ADAM17 siRNA or inhibition of 
ADAM17 activity caused opposite effects using the same metrics (Zheng 2009). In addition, 
knock-down of ADAM17 resulted in a decrease in secretion of transforming growth factor α 
(TGFα) and vascular endothelial growth factor (VEGF), two important factors that increase the 
proliferation of normal or neoplastic epithelial cells and formation of new blood vessels, 
respectively (Zheng 2009). ADAM17 is also called tumor necrosis factor α (TNFα) converting 
enzyme since it is the main enzyme responsible for cleaving TNFα, a pro-inflammatory cytokine 
in inflammation (Zelová & Hošek 2013). Beatriz et al. showed that ADAM17 expression at the 
mRNA and protein levels was increased in senescent p95HER2-exppressing MCF7 cells. HER2 
is an oncogene and its overexpression induces cellular senescence in certain cell lines, such as 
MCF7. Moreover, the results of the same study indicated that ADAM17 sheds different 
transmembrane proteins, such as amphiregulin, an EGFR ligand, upon induction of cellular 
senescence (Morancho 2015). However, another study showed by Western blotting and by a cell 
surface biotinylation assay that ADAM17 protein expression does not increase in senescent PC3 
prostate cancer cells (Effenberger 2014). In that study, cellular senescence was induced by a 
different approach, namely by using a chemotherapeutic drug doxorubicin. In contrast, ADAM17 
activity was increased upon induction of senescence due to the increase of phosphorylation of 
Thr735, one of the well-characterized posttranslational modifications that increase the activity of 
ADAM17. Finally, it was shown that ADAM17 increases the release of amphiregulin and tumor 
necrosis factor receptor 1 (TNFR1) (Effenberger 2014). 
15 
ADAM33 is expressed in different systems in humans, including the respiratory, 
urogenital, gastrointestinal, and endocrine system (Reiss & Saftig 2009; Edwards 2009). 
Although ADAM33 is expressed in many tissues, ADAM33 knock-out in mice showed no 
pathological phenotype (Reiss & Saftig 2009; Edwards 2009). ADAM33 sheds a transmembrane 
protein CD23 (Reiss & Saftig 2009). 
 
EGFR Signaling 
Epidermal growth factor receptor (HER) family is an important modulator of cancer cell 
growth, survival, and metastasis (Kataoka 2009; Foley 2011). The HER family consists of four 
tyrosine kinase receptors, EGFR /HER1, HER2, HER3, and HER4 (Kataoka 2009; Foley 2011). 
These four receptors are activated by different transmembrane ligands. Eleven epidermal growth 
factor receptor (EGFR) ligands have been identified; those are EGF, TGFα, amphiregulin, HB-
EGF, betacellulin, epiregulin, epigen, and neureglulin-1, 2, 3 and 4 (Foley 2011). Each of these 
ligands binds with one or more receptors of the HER family. A characteristic feature of these 
ligands is that they are transmembrane proteins that require cleavage from the cell surface. Upon 
their cleavage, the ligands are released and bind to the corresponding receptor. As a result, a 
homo- or hetero-dimer is formed with another HER family member; this leads to the activation 
of the tyrosine kinase activity. This allows multiple tyrosine residues in the cytoplasmic tail of 
the receptor to be phosphorylated, thereby forming docking sites for different proteins that 
further modulate intracellular signaling pathways, such as the mitogen-activated protein kinase 
(MAPK) pathway, or the phosphoinositide-3 kinase (PI3K) pathway (Kataoka 2009; Foley 2011; 
Montemurro 2013).  
16 
EGFR, HER3, and HER4 need to bind a ligand in order to become active. HER2 does not 
require ligand binding to be activated. Overexpression of HER2 in cancer leads to constitutive 
activation of the downstream signaling pathways, and as a result, sustained stimulation of cell 
proliferation (Montemurro 2013). HER3 lacks the intrinsic tyrosine kinase activity necessary for 
the downstream signaling cascade to occur (Kataoka 2009; Foley 2011). HER4 requires EGFR 
ligands in order to be activated, however, it’s activation leads to reduced proliferation and 
promotion of apoptosis in breast cancer (Koutras 2010).  
In the absence of HER2 overexpression, estrogen receptor (ER)-negative, progesterone 
receptor (PR)-negative, and HER2-negative (or triple negative) breast cancer (TNBC) cells 
depend largely on EGFR to convey the growth signals (Wilson 2009; Foley 2011).   
As mentioned above, EGFR ligands are transmembrane proteins that need to be cleaved 
to interact with and activate their corresponding receptors from the HER family. The cleavage of 
specific EGFR ligand is mediated by one or more ADAMs, such as ADAM9, ADAM10, 
ADAM12, ADAM15, ADAM17, or ADAM19 (Kataoka 2009).  
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Figure 1.7 A diagram of Smad-independent TGFβ downstream pathways. 
Based on Figure 6 from Derynck et al., 2003 with permission from Nature Publishing Group. 
TGFβ signaling activates several other signal proteins and their downstream pathways 
(on the left in green) that do not require involvement of Smads. TGFβ-mediated TAK1 activation 
induces autophagy and thus plays important roles in the regulation of cell apoptosis and survival 
(Choi et al., 2012; Kang et al., 2011). 
 
TAK, TGFβ-activated kinase; AMPK, AMP-activated protein kinase; mTOR, mammalian target 
of rapamycin; NF-κB, nuclear factor-κB; MKK, dual specificity mitogen-activated protein kinase 
kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; Erk, 
extracelluar signal-regulated kinase; ROCK, Rho-associated protein kinase; PP2A, protein 
phosphatase 2A; S6K, ribosomal protein S6 kinase 
 
 
 
Figure 1.1 TGFβ  signaling pathways are mediated either through the canonical, Smad-
dependent or non-canonical, Smad-independent pathways. 
Based on Figure 6 from (Derynck & Zhang 2003), with per ission from Natur  Publishing 
Group. 
TAK, TGFβ-activated kinase; AMPK, AMP activated protein kinase; mTOR, mammalian target 
of rapamycin; NF-κB, Nuclear factor kappa B; MKK, dual specificity mitogen activated protein 
kinase kinase; JNK, c-jun N-terminal kinase; MAPK, mitogen activated protein kinase; Erk, 
extracellular signal regulated kinase; RhoA, Ras homolog gene family, member A; ROCK, Rho-
associated protein kinase; PP2A, protein phosphatase 2A; S6K, ribosomal protein S6 kinase.  
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chemokines can recruit immune cells into tissues and subsequently,
trigger the clearance of both senescent and oncogene-damaged
tumor cells. Secreted metalloproteinases support both tissue repair
and tumor progression. However, chronic inﬂammation is detrimen-
tal in tissues and it is associated with many age-related diseases,
e.g. metabolic disorders and cardiovascular and neurodegenerative
diseases. The aging process itself also involves a low grade inﬂamma-
tion [28,29] but currently, the role of cellular senescence is still
unclear in the aging process.
3. NF-κB signaling is a major inducer of SASP
There has been intensive research examining the signaling mecha-
nisms regulating cellular senescence and SASP. It is now clear that
tumor suppressor proteins p53 and pRB are involved in the appearance
of cellular senescence [14,30]. Their role seems to be linked to the arrest
of cell cycle rather than the induction of inﬂammatory SASP. Several re-
search approaches have revealed that C/EBPβ and NF-κB transcription
factors are involved in the regulation of secretory component of cellular
senescence [17,18,20,31]. Both of these transcription factors have been
implicated in the regulation of cellular stress and inﬂammatory signals.
NF-κB signaling is themajor immune regulator both in adaptive and in-
nate immunity systems [32,33]. C/EBPβ is a potent transcriptional co-
regulator in inﬂammatory responses [34,35] but also in cell cycle regu-
lation, e.g. arresting cellular proliferation via the pRB/E2F complex [36].
There seems to be cooperation between NF-κB and C/EBPβ signaling in
inﬂammatory regulation. For instance, Cappello et al. [37] observed that
C/EBPβ stimulated the NF-κB-dependent signaling by down-regulating
the expression of IκB-α, an inhibitory κB component. NF-κB and C/EBPβ
havemany synergistic effects, e.g. in the induction of CRP expression via
the IL-1β-stimulated autocrine IL-6 loop [38,39] but in some instances,
C/EBPβ can also block NF-κB signaling and inﬂammation [40]. It seems
that C/EBPβ is a context-dependent regulator of inﬂammation, probably
due to its capacity to interact with several signalingmolecules and tran-
scription factors [41].
Three recently published articles using different research models
have convincingly demonstrated that it is the NF-κB signaling which
promotes the presence of SASP in cellular senescence [9–11]. Chien
et al. [9] observed that NF-κB signaling controlled the appearance of
SASP in a well-characterized H-RasV12-induced senescence model
with human IMR-90 skin ﬁbroblasts. They demonstrated that the
p65 subunit of NF-κB complex was more signiﬁcantly enriched into
the chromatin of senescent ﬁbroblasts as compared to that of young
counterparts. Immunohistochemistry revealed that p65 was accumu-
lating into the SAHF-positive nuclei. They also observed that p65 was
clearly phosphorylated on Ser536, a transactivating modiﬁcation,
which correlated with increased expression and secretion of inﬂam-
matory markers. Microarray proﬁling showed that p53 and NF-κB
controlled distinct transcriptional modules but were complementary
since the down-regulation of p65 was sufﬁcient to bypass the H-
RasV12-induced senescence in human ﬁbroblasts [9]. Rouvillain et al.
[11] demonstrated that stimulation of the p53–p21Cip1 pathway pre-
dominantly evoked to cellular senescence in human ﬁbroblasts. They
also observed that senescence was associated with a prominent SASP,
with IL-1α and IL-1β being the most highly up-regulated genes. Inter-
estingly, they observed that the cell cycle arrest provoked by serum
starvation induced similar inﬂammatory changes as oncogene-
induced SASP. Rouvillain et al. [11] also revealed that the inhibition
of NF-κB signaling could overcome the growth arrest induced by
p53–p21Cip1 signaling which implies that the NF-κB pathway had a
causative role in the induction of SASP.
4. Signaling pathways activating NF-κB system in SASP
The NF-κB system is an evolutionarily conserved signaling path-
way which can be triggered not only by immune activation but also
Fig. 1. A general overview on the potential signaling pathways which can control the activity of IKK and NF-κB complexes and subsequently the induction of SASP. Genotoxic stress
stimulates NF-κB signaling via different pathways including the NEMO shuttle and both p38MAPK and RIG-1pathways. Environmental stress (without DNA damage) activates the
p38MAPK pathway and ceramide production. Inﬂammatory components activate the IKK complex via signaling pathways involving complexes assembled by TRAFs and TAK1.
HMGB1 can enhance inﬂammatory responses both in nuclei and after secretion. p16INK4a and p14ARF proteins are direct inhibitors of NF-κB signaling. Abbreviations: ATM, Ataxia
Telangiectasia Mutated; C/EBPβ, CCAAT/enhancer binding protein β; ELKS, a protein rich in glutamic acid, leucine, lysine and serine; HMGB1, high mobility group box protein 1;
IKKα/β, IκB kinase α and β; IL-1β, interleukin-1β; IRF-1, interferon regulatory factor-1; LUBAC, linear ubiquitin chain assembly complex; p38MAPK, mitogen-activated protein ki-
nase; MAVS, mitochondrial antiviral-signaling protein; MSK1/2, mitogen- and stress-activated protein kinases 1 and 2; NEMO, NF-κB essential modiﬁer; NF-κB, nuclear factor-κB;
p14ARF, alternate reading frame product of p16INK4a; p16INK4a, cyclin-dependent kinase inhibitor 2A; PARP-1, poly(ADP-ribose) polymerase-1; PIDD, p53-induced protein with a
death domain; PKCζ, protein kinase Cζ; RIG-1, retinoic acid inducible gene-1; RIP1, receptor interacting protein 1; SASP, senescence-associated secretory phenotype; SIRT6, silent
information regulator 6; TAB, TAK1-binding protein; TAK1, TGFβ-activated kinase 1; TGFβ, transforming growth factor β; TMEM9B, transmembrane protein 9B; TNFα, tumor ne-
crosis factor α; TRAFs, TNF-receptor-associated factors; WIP1, protein phosphatase 2Cδ.
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Figure 1.2 Different signaling pathways can regulate NF-κB. 
Based on Figure 1 from (Salminen 2012), no changes were made to the figure. 
The link to the license: https://creativecommons.org/licenses/by-nc-nd/3.0/ 
ATM, Ataxia telangiectasia mutated; C/EBPβ, CCAAT/enhancer binding protein β; ELKS, a 
protein rich in the following amino ac ds: glutamic acid, leuci e, lysine, and se ine; HMGB , 
high mobility group box 1; IKKα/β, IκB kinase α and β; IL-β, interlukin-1β; IRF-1, interferon 
regulatory factor-1; LUBAC, linear upiquitin chain assembly complex; p38MAPK, mitogen-
activated prot in kinase; MAVS, mitochondrial antiviral-sign ling protein; MSK1/2, mitogen- 
and stress-activated protein kinases 1 and 2; NEMO,  NF-κB essential modifier; p14ARF, 
alternate reading frame product of p16INK4a; p16INK4a, cyclin dependent kinase inhibitor 2A; 
PARP-1, poly (ADP- ibose) polyme a e-1; PIDD, p53-induced protein with a d ath domain; 
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PKCζ, protein kinase Cζ; RIG-1, retinoic acid inducible gene-1; RIP1, receptor interacting 
protein 1; SIRT6, silent information regulator 6;  TAB, TAK1-binding protein; TMEM9B, 
transmembrane protein 9B; TNFα, tumor necrosis factor α; TRAFs, TNF-receptor-associated 
factors; WIP1, protein phosphatase 2Cδ. 
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Figure 1.3 Domain organizations of ADAM metalloproteases. 
Based on Figure 2 from (Murphy 2008), with permission from Nature Publishing Group. 
PRO, prodomain; MP, metalloprotease; DIS, disintegrin; CR, cysteine-rich; EGF, EGF-like; TM, 
transmembrane; CD, cytoplasmic domain, HVR, hypervariable region.  
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Chapter 2 - Expression of ADAM Metalloproteases during 
Transforming Growth Factor β-Induced Senescence in Breast 
Cancer Cells  
Abstract  
Cellular senescence is a state of irreversible cell cycle arrest in response to different 
inducers. Many inducers, intrinsic and extrinsic, have been identified to cause senescent growth 
arrest; for example, transforming growth factor β (TGFβ). Senescent cells secrete different 
factors, such as inflammatory cytokines, chemokines, or matrix remodeling factors. Those 
factors affect neighboring cells by increasing their proliferation, inducing epithelial-
mesenchymal transition (EMT), or causing other effects. Some of the secreted factors are 
transmembrane proteins that require cleavage from the surface of senescent cells in order to be 
released and to affect neighboring cells. A Disintegrin and Metalloprotease (ADAM) family 
proteins are sheddases for many transmembrane proteins.  
In the present study, we tried to induce cellular senescence in two breast cancer cell lines, 
SUM102PT and SUM149PT cells, using TGFβ, followed by treating the cells with a high dose 
of paclitaxel to remove the actively proliferating, non-senescent cells. The induction of cellular 
senescence was tested using senescence associate β galactosidase (SA-β-gal) staining and 
assessment of cell size and granularity. The induction of cellular senescence was confirmed in 
SUM102PT cells. The mRNA expression levels of different catalytically active ADAMs; 
ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, ADAM 19, and ADAM28, were 
investigated. Among these ADAMs, the mRNA level of ADAM12 was significantly upregulated 
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in SUM102PT cells upon induction of senescence. Further investigations are needed to test 
ADAM12 protein expression upon induction of cellular senescence.  
   
Introduction 
Cellular senescence represents a response of cells to non-lethal stress (Shay & Roninson 
2004; Rodier & Campisi 2011; Campisi 2014). Senescent cells undergo an irreversible cell cycle 
arrest to prevent the transmission of the damage to daughter cells and to prevent neoplastic 
transformation (Campisi 2014; Sabin & Anderson 2011).  
Senescent cells have different characteristic features: 1) Unlike quiescent cells, senescent 
cells are not able to re-enter the cell cycle upon proliferative stimuli. 2) Senescent cells are 2-fold 
larger than their non-senescent counterparts. 3) Senescent cells have profound changes in their 
chromatin organization and have different types of nuclear foci, such as DNA-SCARS and 
SAHF foci. 4) Senescent cells have increased activity of the SA-β-gal enzyme. 5) Senescent cells 
are metabolically active and secrete different factors, such as cytokines, chemokines, matrix 
remodeling enzymes, and growth factors. This secretory phenotype is called senescence 
associated secretory phenotype (SASP). Collectively, those hallmarks define the senescent state 
(Rodier & Campisi 2011; Campisi 2014; Shay & Roninson 2004; Campisi & d’Adda di Fagagna 
2007). 
SASP components have both beneficial and deleterious effects. In cancer, some SASP 
components maintain the senescent state. On the other hand, other SASP components promote 
tumor growth by increasing cell proliferation or inducing EMT. Therefore it is important to 
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understand the mechanisms that lead to the release of SASP factors from senescent cells (Rodier 
& Campisi 2011; Coppé 2010).  
Different agents or treatments can induce cellular senescence. TGFβ is an example of 
such agents (Salminen 2012; Campisi 2014). Besides induction of cellular senescence, TGFβ 
induces and modulates other processes in the cells. For example, TGFβ induces EMT, a 
developmental process that occurs in normal tissues and in tumors. Moreover, TGFβ regulates 
cell growth, differentiation, and apoptosis (Derynck & Zhang 2003; Vijayachandra 2009; Heldin 
1997).      
A disintegrin and metalloproteases (ADAMs) are able to proteolytically cleave many 
transmembrane proteins, which have been found to be integral parts of SASP (Coppé 2010; 
Reiss & Saftig 2009). Moreover, expression of several ADAMs is upregulated in different 
cancers including breast cancer, which reflects the relevance of those ADAMs for carcinogenesis 
(Edwards et al. 2009). 
The goal of this study was to test the expression levels of different catalytically active 
ADAMs upon induction of cellular senescence in breast cancer cell lines. We identified 
ADAM12 as a novel metalloprotease that is upregulated at the mRNA level upon induction of 
cellular senescence in SUM102PT cells. ADAM12 protein expression at the cell surface was also 
examined by flow cytometry. However, since senescent cells are significantly larger than their 
non-senescent counterparts, we were not able to definitely establish whether the slight increase in 
the anti-ADAM12 staining in senescent cells was as a result of upregulation of ADAM12 or 
increased non-specific binding of anti-ADAM12 antibody. Additional investigations are needed 
to test ADAM12 protein at the cell surface of senescent cells. 
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If ADAM12 is indeed upregulated in senescent cells, it may play a role in releasing 
certain SASP components. Thus, targeting ADAM12 could be used as a strategy to block the 
release of these SASP components. 
 
Materials and Methods 
Reagents and antibodies 
Senescence β-Galactosidase Staining (SA-β-Gal staining) Kit (#9860) was from Cell 
Signaling Technology. Antibodies used for flow cytometry were: anti-ADAM12 (clone 632525) 
and IgG1 isotype control (clone 11711), both from R&D Systems. Allophycocyanin (APC)-
conjugated anti-mouse IgG antibody was from Jackson ImmunoResearch. Other reagents used 
include paclitaxel (Sigma-Aldrich), TGFβ (R&D) and propidium iodide (BD Biosciences).  
 
Cell culture 
SUM149PT cell line was purchased from Asterand. SUM102PT cells were a gift from 
Dr. Fariba Behbod (University of Kansas Medical Center). SUM149PT cells were cultured in 
Ham’s F-12 medium supplemented with 5% fetal bovine serum (FBS), 10 mM HEPES, 5 µg/ml 
insulin, and 1 µg/ml hydrocortisone. SUM102PT cells were cultured in Ham’s F-12 medium, 
which was supplemented with 5% FBS, 1 µg/ml hydrocortisone, and 5 µg/ml insulin. Cells were 
maintained at 37°C under humidified atmosphere containing 5% CO2. 
 
Flow cytometry   
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ADAM12 staining: SUM102PT cells were treated with or without 2 ng/ml TGFβ for 10 
days. At day 6, cells were treated with or without 200 nM paclitaxel for 4 days. Cells were 
trypsinized, washed, and prepared as a single cell suspension at 106 cells/100 µl in DPBS with 
3% BSA. Cells were incubated with either anti-ADAM12 or IgG1 isotype control antibody at 
1:10 dilution (25 µg/ml) for 30 minutes on ice. Then, cells were washed three times with DPBS 
and incubated with APC-conjugated anti-mouse IgG antibody at 1:50 dilution for 30 minutes on 
ice. Finally, cells were washed with DPBS and suspended in 500 µl DPBS containing 3% BSA. 
Cells were analyzed with a BD FACS Calibur cytometer. All data were analyzed with the FCS 
Express 4 software (DeNovo Software). 
  
Cell survival assay 
SUM149PT or SUM102PT cells were treated with or without 2 ng/ml of TGFβ for 10 
days. At day 6, cells were detached, counted by a cellometer, and seeded into a 96-well plate at 
3000-5000 cells/well. Cells were then treated with various doses of paclitaxel until day 10. At 
day 10, viable cells were evaluated using CellTiter-Glo Luminescent Cell Viability Assay 
(Promega) and Synergy H1 microplate reader (BioTek); at least 3 wells per each cell type were 
measured for each dose of paclitaxel. The dose response for paclitaxel was calculated using the 
GraphPad Prism software. 
 
β-Galactosidase staining  
SUM149PT or SUM102PT cells were incubated with or without 2 ng/ml TGFβ for 10 
days. At day 6, cells were treated with or without 100 nM (SUM149PT cells) or 200 nM 
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(SUM102PT cells) paclitaxel for additional 4 days. At day 10, cells were fixed for 15 minutes, 
followed by applying β-Galactosidase staining solution and incubation overnight at 37°C. Cells 
were examined by light microscopy for the development of blue color and several images were 
acquired using a 4X objective. 
 
Quantitative real-time PCR  
Total RNA was extracted using the Qiagen RNeasy kit and subjected to on-column 
digestion with deoxyribonuclease I.  One microgram of total RNA was reverse-transcribed using 
the SuperScript III First Strand Synthesis system (Invitrogen). Quantitative real time-PCR (qRT-
PCR) was performed on a BioRad CFX96 instrument. At the end of each run, a melt curve 
analysis was performed to ensure that a single product had been synthesized. The relative 
expression of each gene, normalized to actin, was calculated using the 2-ΔΔCt method. 
Table 2.1 Primer sequences. 
Type	of	primers	 Primer	sequence	
ADAM8	
F	 5'-AGG	CTC	AGC	TGC	TGT	TCT	AA-3'	
R	 5'-CAC	CTG	GAG	ACA	CGT	ACA	CA-3'	
ADAM9	
F	 5'-GAC	TCA	GAG	GAT	TGC	TGC	AT-3'	
R	 5'-GAG	GCT	CTT	CTT	CTT	CAT	CC-3'	
ADAM10	
F	 5'-AGC	AAC	ATC	TGG	GGA	CAA	AC-3'	
R	 5'-CCC	AGG	TTT	CAG	TTT	GCA	TT-3'	
ADAM12	
F	 5'-AGC	CAC	ACC	AGG	ATA	GAG	AC-3'	
R	 5'-CGC	CTT	GAG	TGA	CAC	TAC	AG-3'	
ADAM15	
F	 5'-CTT	CAG	GGT	CCT	CCC	ATT	AT-3'	
R	 5'-ATC	AGC	CAC	AAT	CAC	CAA	CT-3'	
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ADAM17	
F	 5'-CTG	TGG	TGC	AAA	AGC	AGA	AA-3'	
R	 5'-TGC	CAA	ATG	CCT	CAT	ATT	CA-3'	
ADAM19	
F	 5'-CTG	ATT	ACG	GTG	AGC	AGC	AA-3'	
R	 5'-TCG	CTT	CTT	GGT	CTG	TTG	TG-3'	
ADAM28	
F	 5'-ATG	CTG	TGT	GTG	ACC	ATG	AG-3'	
R	 5'-CGG	ATT	ACC	ATA	GCA	ACC	AC-3'	
β-	Actin	
F	 5'-TTG	CCG	ACA	GGA	TGC	AGA	A-3'	
R	 5'-GCC	GAT	CCA	CAC	GGA	GTA	CT-3'	
 
 
Results 
TGFβ-induced senescence in breast cancer cell lines 
To examine the expression levels of different ADAM metalloproteases during 
senescence, we used TGFβ to induce cellular senescence in two breast cancer cell lines, 
SUM102PT and SUM149PT. Since TGFβ may induce different phenotypes, in addition to 
cellular senescence (Figure 2.1a), cells were treated with paclitaxel (PTX), a chemotherapeutic 
drug to remove actively proliferating cells and enrich for senescent cell populations. PTX is an 
antimitotic agent that binds to microtubules during mitoses and stabilizes them and, as a result, 
causes an arrest at the G2/M phase, followed by apoptosis (Fan 1999). Senescent cells are 
resistant to PTX because they are not proliferative. 
First, we performed a dose response to PTX in SUM102PT or SUM149PT cells that were 
either treated or untreated with 2 ng/ml TGFβ for 6 days. At day 6, TGFβ treatment continued 
and cells were treated with different doses of PTX for additional 4 days. We observed that there 
was a small population of cells that were resistant to high doses of PTX in both cell lines, 
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SUM102PT and SUM149PT (Figure 2.1 b and c). We didn’t observe a similar effect in 
SUM159PT cells (data are not shown), another breast cancer cell line. These results suggested 
that TGFβ might act as an inducer of cellular senescence in SUM102PT and SUM149PT, but not 
in SUM159PT cells.  
To further examine the properties of SUM102PT and SUM149PT cells treated with 
TGFβ and PTX, we used flow cytometry to measure the forward scatter (FSC) and the side 
scatter (SSC). FCS and SSC are indicative of the size and complexity of the cells, respectively 
(Shinohara 2000; Hégaret 2003). Cells treated with TGFβ and with 200 nM (in the case of 
SUM102PT) or 100 nM (in the case of SUM149PT) PTX were significantly larger and more 
complex than untreated cells (Figure 2.2 a and b, respectively).  
Next, we performed a β-Galactosidase staining assay for either untreated cells or cells 
treated with TGFβ and PTX in both SUM102PT and SUM149PT cells (Figure 2.2 c and d, 
respectively). Many SUM102PT cells were stained blue after they were treated with TGFβ and 
PTX. However, we detected very few β-Gal-positive SUM149 cells after treatment with TGFβ 
and PTX. Moreover, after 4 days of recovery, SUM102PT cells appeared positive for β-Gal and 
didn’t resume proliferation. SUM149PT cells, in contrast, didn’t appear to be positive for β-
Galactosidase, although they were not able to proliferate during the 4-day recovery period. 
The increases in size, complexity, upregulation of β-Galactosidase expression, and the 
lack of the proliferation during the recovery period, were consistent with the features of 
senescent cells. We concluded that TGFβ treatment, followed by PTX-mediated elimination of 
proliferating cells, resulted in senescence in SUM102PT cells. The induction of senescence in 
SUM149PT cells was less clear.  
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Survey of ADAM expression in senescent cells   
To answer the question of which ADAMs are upregulated upon induction of cellular 
senescence, we measured the mRNA levels of ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, 
ADAM17, ADAM 19, and ADAM28 in SUM102PT senescent cells (Figure 2.3). The same 
ADAM were also tested in SUM149PT cells (Figure 2.4). These eight ADAMs are catalytically 
active and broadly expressed. The results showed that the mRNA expression of ADAM12 was 
significantly increased upon induction of cellular senescence in SUM102PT cells. Interestingly, 
the mRNA expression of ADAM28 was also increased in senescent cells. mRNA expression of 
tested ADAM followed the same trend in SUM149PT cells, although the increase ADAM12 and 
ADAM28 was not significant.    
 
Cell surface expression of ADAM12 in senescent cells 
Finally, we examined ADAM12 protein levels by flow cytometry. We observed a small 
increase in ADAM12 staining in senescent cells compared to non-senescent cells (Figure 2.4 a 
and b). ADAM12 expression was also increased in SUM149PT cells after TGFβ and PTX 
treatment (Figure 2.4 c and d). However, flow cytometry experiments had important limitations. 
As mentioned previously, senescent cells are larger than their non-senescent counterparts and 
they have high level of non-specific staining. Therefore, it is possible that increased ADAM12 
staining observed in senescent cells was caused by a higher level of background non-specific 
staining. Clearly, more investigations are needed to evaluate ADAM12 protein expression in 
senescent cells.  
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Discussion 
Cellular senescence is a state of irreversible cell cycle arrest in response to a variety of 
non-lethal stress conditions (Coppé 2010; Freund 2010). For a long time, this process was 
considered inhibitory during tumorigenesis. However, it was later discovered that senescent cells 
secrete various proteins, such as cytokines, chemokines, growth factors, and matrix remodeling 
enzymes. This feature has been termed SASP. SASP components may promote carcinogenesis 
by increasing cell proliferation and/or inducing EMT, among others. A group of SASP 
components are expressed at the surface of senescent cells as transmembrane proteins; those 
proteins need to be cleaved in order to act on their prospective targets (Rodier & Campisi 2011; 
Freund 2010; Coppé 2010). Since the catalytically active ADAMs act as sheddases for different 
transmembrane proteins that are SASP components, we tested the expression levels of different 
ADAMs upon induction of cellular senescence. 
In this report, we examined the induction of cellular senescence in two breast cancer cell 
lines, SUM102PT and SUM149PT. We used TGFβ as an inducer of cellular senescence 
(Salminen 2012). While senescence was confirmed in SUM102PT cells, unfortunately, we were 
not able to detect β-Galactosidase staining in SUM149PT cells after a 4-day recovery period, 
which suggested that those cells might not be senescent. While TGFβ- and PTX- treated 
SUM149PT cells had increased size and complexity and they didn’t resume proliferation after a 
recovery period, those features are not exclusive to senescent cells and they should not be treated 
as a strong evidence of senescence. 
 The expression levels of several catalytically active ADAMs, namely ADAM8, ADAM9, 
ADAM10, ADAM12, ADAM15, ADAM17, ADAM 19, and ADAM28, were tested. ADAM12 
mRNA expression level was significantly increased upon induction of senescence in SUM102PT 
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cells. One of the identified intracellular pathways that increases ADAM12 expression is the NF-
κB pathway (Ray et al. 2010). Ray et al. identified NF-κB responsive elements in the ADAM12 
promoter and demonstrated that NF-κB increases ADAM12 expression. This could be a possible 
reason for the upregulation of ADAM12 expression during senescence, since TGFβ induces 
cellular senescence and SASP via the activation of the NF-κB transcription factor. 
Another important observation in this report is that the expression level of ADAM17 
didn’t change upon induction of cellular senescence. These results do not agree with the results 
published by Morancho et al., who showed that ADAM17 mRNA levels in MCF7 cells were 
increased upon induction of cellular senescence via the expression of p95HER2 (Morancho 
2015). On the other hand, our results agree, indirectly, with the results published by Effenberger 
et al., who showed that although ADAM17 expression didn’t change upon induction of cellular 
senescence in PC3 cells, the activity of ADAM17 protease was increased (Effenberger 2014). 
The possible explanation for this discrepancy may lie in using different cell lines in each study, 
or using different approaches to induce cellular senescence, or both.   
In summary, our results demonstrate that ADAM12 mRNA expression was increased in 
senescent cells. This upregulation of ADAM12 mRNA may have important implications, if it is 
indeed accompanied by an increase in ADAM12 protein level. ADAM12 protease might release 
specific SASP components that could have an impact on the tumor microenvironment. Further 
investigations are needed to test ADAM12 protein expression. Cell surface biotinylation assays 
could be used as an alternative technique to evaluate ADAM12 expression at the cell surface and 
to overcome the limitations of flow cytometry experiments. If ADAM12 expression is 
upregulated in senescent cells and is associated with releasing SASP components, then this work 
may have important implications in cancer therapy. Targeting ADAM12 to block senescence-
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associated ectodomain shedding might be a more efficient approach than targeting individual 
SASP components.   
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Figure 2.1 Small populations of cells are resistant to high doses of paclitaxel after TGFβ 
treatment in SUM102PT and SUM149PT cell lines. 
(Panel c was performed by Yue Qi.)  
(a) A cartoon showing the effect of TGFβ on proliferating cell. Treatment with high doses of 
paclitaxel targets actively proliferating cells. (b) SUM102PT cells and (c) SUM149PT 
cells were treated with or without 2 ng/ml TGFβ for 10 days. At day 6, cells were treated 
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with different concentrations of paclitaxel for 4 days. CellTiter-Glo assay was used to 
assess cell viability. Sigmoidal dose response curves were fitted using the GraphPad 
Prism software. Values were calculated from triplicate wells for each dose of paclitaxel. 
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Figure 2.2 TGFβ treatment induces cellular senescence in SUM02PT cells. 
(a-b) Representative flow cytometry measurement of the forward scatter (FSC) and side scatter 
(SSC) of SUM102PT cells (a) and SUM149PT cells (b). Cells were either untreated or treated 
with 2ng/ml TGFβ for 10 days and 100 nM (SUM149PT cells, n=3) or 200nM (SUM102PT 
cells, n=2) paclitaxel from day 6 to day 10. (c-d) SA-β-Gal staining. Representative phase-
contrast images of SUM102PT cells (c) or SUM149PT cells (d) that were either untreated or 
treated with 2 ng/ml TGFβ for 10 days, including 100 nM (SUM149PT cells) or 200 nM 
(SUM102PT cells) paclitaxel from day 6 to day 10, and then allowed to recover for 4 days (n=1-
2).  
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Figure 2.3 Survey of ADAM expression in senescent SUM102PT cells. 
(a-h) SUM102PT cells were treated with or without 2 ng/ml TGFβ for 10 days. At day 6, cells 
were treated with or without 200 nM paclitaxel. ADAM8 (a), 9 (b), 10 (c), 12 (d), 15 (e), 17 (f), 
19 (g), and 28 (h) mRNA levels were measured by qRT-PCR and normalized to β-ACTIN. Fold 
change in TGFβ-treated or TGFβ- and paclitaxel-treated cells versus untreated cells were shown 
as the average values ± SEM, (n=2 for ADAM8, ADAM9, ADAM10, and ADAM15; n=3 for 
ADAM12, ADAM19, and ADAM28; one sample t test, * p<0.05).   
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Figure 2.4 Survey of ADAM mRNA expression in senescent SUM149PT cells. 
(a-h) SUM149PT cells were treated with or without 2 ng/ml TGFβ for 10 days. At day 6, cells 
were treated with or without 100 nM paclitaxel. ADAM8 (a), 9 (b), 10 (c), 12 (d), 15 (e), 17 (f), 
19 (g), and 28 (h) mRNA levels were measured by qRT-PCR and normalized to β-ACTIN. Fold 
change in TGFβ-treated or TGFβ- and paclitaxel-treated cells versus untreated cells were shown 
as the average values ± SEM, (n=3 for ADAM8, ADAM9, ADAM10, and ADAM15, n=4 for 
ADAM12, ADAM19, and ADAM28; one sample t test, * p<0.05).   
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Figure 2.5 ADAM12 protein expression at the cell surface upon induction of senescence in 
SUM102PT cells. 
(a, c) ADAM12 protein expression at the cell surface was evaluated by flow cytometry in 
SUM149PT cells (a) and SUM102PT cells (c). Untreated cells or cells treated with 2 ng/ml 
TGFβ for 10 days and 100 nM (SUM149PT cells) or 200 nM (SUM102PT cells) paclitaxel from 
day 6 to day 10 were stained with an anti-ADAM12 (red) or IgG1 isotype control (grey). The 
cells were then incubated with APC-conjugated anti-mouse IgG antibody. (b, d ) The difference 
in median fluorescence intensity (ΔMFI) in SUM102PT cells (b) and SUM149PT cells (d) were 
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determined in one experiment in (b) and three independent experiments in (d). The results are 
shown as means ± SEM, *, p<0.05.  
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Chapter 3 - ADAM12 Activates EGFR Signaling through the 
Cleavage of EGFR Ligands 
 
Abstract 
Epidermal growth factor receptor (EGFR), also called HER1 or ErbB1, is a member of 
the ErbB family. EGFR requires a ligand binding to dimerize, autophosphorylate, and stimulate 
its tyrosine kinase activity. EGFR signaling plays an important role in cell proliferation, survival, 
and tumor metastasis in triple negative breast cancer (TNBC). Soluble EGFR ligands are derived 
from their transmembrane precursors by ADAM metalloproteases, however, the specific role of 
ADAM12 in activating EGFR in breast cancer cells has not been explored.  
Here, we demonstrate that ADAM12 activates the EGFR pathway via releasing EGFR 
ligands rather than acting upon EGFR itself. Using the SUM159PT breast cancer cell line, we 
detected basal activation of EGFR by measuring the phosphorylation of a tyrosine residue in the 
cytoplasmic tail of EGFR, pY1068, using Western blotting. This phosphorylation was increased 
in cells treated with EGF, an EGFR activator, and decreased in cells treated with erlotinib, an 
EGFR inhibitor. The basal activation of EGFR resulted from the endogenously produced EGFR 
ligands, and ADAM12 knock-down decreased the level of pY1068. Batimastat, a 
metalloprotease inhibitor, and exogenous EGF blocked the effect of ADAM12 knockdown on 
pY1068. Moreover, the phosphorylation of Y1068 was not changed in MCF10A cells stably 
expressing ADAM12 compared to the control cells treated with different doses of exogenous 
hEGF for 10 or 30 minutes. Finally, co-immunoprecipitation was performed to test a direct 
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physical interaction between ADAM12 and EGFR; no interaction between these two proteins 
was detected. These results indicate that ADAM12 activates EGFR and this activation occurs 
most likely through the release of EGFR ligands.  
  
Introduction 
EGFR/HER1/ErbB1 is a member of the ErbB family. The ErbB family is composed of 
four receptors: Epidermal growth factor receptor (EGFR/HER1/ErbB1), HER2/ErbB2, 
HER3/ErbB3, and HER4/ErbB4 (Kataoka 2009; Hynes & MacDonald 2009). EGFR is activated 
upon its binding to different EGFR ligands. As a result of ligand binding, autophosphorylation 
and activation of the tyrosine kinase domain takes place. HER2 is constitutively active and does 
not require ligand binding for activation. On the other hand, HER3 requires ligand binding but it 
is a kinase-defective receptor and it is phosphorylated only when dimerized with another HER 
family receptor. Signaling by EGFR, HER2, and HER3 stimulates breast cancer cell 
proliferation, survival, and tumor metastasis (Foley 2011). HER4 is a unique member in the 
ErbB family; despite the fact that HER4 requires EGFR ligands for activation and has a tyrosine 
kinase activity, it elicits an antiproliferative response in mammary epithelium (Muraoka-Cook 
2008).  
Ligand-mediated EGFR activation is essential to promote tumor growth and progression 
in triple negative breast cancer (TNBC), in the absence of HER2 overexpression (Kataoka 2009; 
Wilson 2009).   
Eleven EGFR ligands have been identified: epidermal growth factor (EGF), tumor 
growth factor α (TGFα), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, 
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epigen, epiregulin, betacellulin, and neureglulin-1, 2, 3 and 4 (Foley 2011). These ligands are 
synthesized as transmembrane proteins that require shedding from the membrane in order to be 
released, to bind, and to activate target receptor/s. Ligand shedding is mediated predominantly 
via members of the ADAM (a disintegrin and metalloprotease) family. Different ADAMs are 
capable of generating soluble EGFR ligands (Kataoka 2009). ADAM12 is one of the 
catalytically active ADAMs that is strongly upregulated in breast tumors (Li et al. 2012a; 
Fröhlich 2011; Roy 2011). It has been shown that ADAM12 is capable of cleaving HB-EGF 
(Asakura, 2002). Moreover, RNA sequencing experiments, which were performed in our 
laboratory by Dr. Sara Duhachek-Muggy, showed that the gene expression changes upon 
ADAM12 knock-down were similar to changes observed after inhibition of EGFR signaling 
(Duhachek-Muggy and Qi 2017). These results led us to hypothesize that ADAM12 might 
modulate the EGFR signaling pathway. 
The goal of this study was to examine whether ADAM12 is capable to activate EGFR in 
breast cancer cells and whether this activation is achieved by increasing the release of EGFR 
ligands or by direct interactions with EGFR. Our results suggest that ADAM12 activates EGFR 
signaling through the release of EGFR ligands. 
 
Materials and Methods 
Reagents and antibodies 
ADAM12 siRNA#1 (D-005118-01), ADAM12 siRNA#2 (D-005118-02), ON-
TARGETplus non-targeting siRNA pool (D-001810-10), and DharmaFECT1 transfection 
reagent were obtained from GE Dharmacon. Batimastat (BB-94) was from EMD Millipore, 
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erlotinib was from Cell Signaling, and human recombinant EGF was from Life Technologies. 
Antibodies used for Western blotting were: rabbit monoclonal anti-pY1068 EGFR (clone D7A5), 
anti-total EGFR (clone D38B1), and anti-total MEK 1/2 (clone D1A5), all from Cell Signaling. 
Anti-α-tubulin (clone DM1A) was from Sigma-Aldrich.  
 
Cell culture 
SUM159PT cell line was purchased from Asterand. MCF10A cells were purchased from 
American Type Culture Collection. SUM159PT cells were cultured in Ham’s F-12 medium 
supplemented with 5% fetal bovine serum (FBS), 10 mM HEPES, 5 µg/ml insulin, and 1 µg/ml 
hydrocortisone. MCF10A cells were cultured in DMEM/F-12 medium supplemented with 5% 
horse serum, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 20 ng/ml human EGF, and 100 ng/ml 
cholera toxin. Cells were maintained at 37°C under humidified atmosphere containing 5% CO2. 
 
Western Blotting 
Cells were lysed using sample buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris-
HCl pH (7.4), 0.5 % sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS), 5 mM EDTA, 
protease inhibitors (1 mM AEBSF, 5 µg/ml pepstatin, 5 µg/ml leupeptin, 10 mM 1,10-
phenathroline, and 5 µg/ml aprotinin), and phosphatase inhibitors (50mM NaF, 2mM Na3VO4, 
and 10 mM Na4P2O7). All lysates were freshly prepared and resolved by SDS-PAGE (8% gel), 
and then Western blotting was performed. The following primary antibodies were used: anti-
ADAM12 antibody (Ab# 3394 (Li et al. 2012b)) raised against the cytoplasmic tail of human 
ADAM12 and used at 1:10,000 dilution, rabbit monoclonal anti-pY1068 EGFR at 1:5,000 
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dilution, anti-total EGFR at 1:5,000 dilution, anti-total MEK 1/2 at 1:5,000 dilution, and anti-α-
tubulin at 1:200,000 dilution. Horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG 
antibody were used as a secondary antibody at 1:5,000 dilution. The signal was detected using 
SuperSignal West Pico chemiluminescence detection kit (Pierce) and an Azure c500 digital 
imaging system. 
 
Immunoprecipitation assay 
MCF10A.ADAM12 or MCF10A.EV cells, which were established as previously described (Li et 
al. 2013), were lysed, and 400 µl cell lysate was incubated with either anti-ADAM12 antibody 
(clone 632525) or IgG1 control antibody (clone 11711), both from R&D Systems, at 10 µg/ml 
concentration overnight at 4°C. On the following day, 40 µl of protein G-Sepharose (GE 
Healthcare, 1:1 slurry) was added to each sample and incubated for 1 hour. Beads were washed 
three times with lysis buffer. Proteins were eluted in SDS sample buffer, fractionated by SDS-
PAGE (8% gel), and Western blotting was performed. The following primary antibodies were 
used: anti-ADAM12 antibody (Ab# 3394 (Li et al. 2012)) at 1:10,000 dilution, and anti-total 
EGFR (clone D38B1) at 1:5,000 dilution. Horseradish peroxidase-conjugated anti-rabbit IgG 
antibody were used as a secondary antibody at 1:5,000 dilution. The signal was detected using 
SuperSignal West Pico chemiluminescence detection kit (Pierce). 
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Results 
The basal activation of EGFR is mediated by endogenously expressed ligands in SUM159PT 
cells 
We first examined the basal activation level of EGFR in SUM159PT cells, a TNBC cell 
line, by measuring the phosphorylation at Tyr 1068, pY1068. This Tyr residue is one of the 
major autophosphorylation sites in EGFR and often serves as a read-out for the activation status 
of the receptor. The level of pY1068 was decreased upon treating cells with 1 µM erlotinib, an 
EGFR inhibitor, and increased when cells were treated with hEGF, an EGFR activator. This 
confirmed that EGFR receptor was fully functional in SUM159PT cells (Figure 3.1 a).  
  Next, we asked whether the basal activation of EGFR was mediated by the 
endogenously expressed EGFR ligands, which require ADAM proteases in order to be released 
from cells, or by EGF-like factors that might be present in the serum-supplemented culture 
media. SUM159PT cells were incubated with 0, 10, or 50 µM batimastat (BB-94), a 
metalloprotease inhibitor, in the presence or absence of serum in the culture media for 24 hours 
(Figure 3.1 b). The phosphorylation of Y1068 was decreased in cells treated with BB-94, 
regardless of the presence or absence of serum. These results suggest that the basal activation of 
EGFR is achieved through the endogenously expressed EGFR ligands that require ADAM-
mediated cleavage, rather than exogenous EGF that might be present in the serum.   
   
ADAM12 knock-down does not change EGFR responsiveness to EGF   
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To explore the role of ADAM12 in the activation of EGFR, SUM159PT cells were 
transfected with either control siRNA or two individual siRNAs targeting ADAM12, siA12#1 
and #2. Transfected cells were incubated in serum-free medium or in complete medium that 
contained serum. Down-regulation of ADAM12 reduced the level of pY1068 regardless of the 
presence or absence of serum (Figure 3.2 a). The effect of knock-down of ADAM12 on EGFR 
phosphorylation was eliminated when cells were incubated with 10 µM BB-94 or 20 ng/ml 
hEGF (Figure 3.2 b). Moreover, the rate of the phosphorylation of Y1068 was not changed in 
MCF10A cells stably expressing ADAM12, MCF10A.ADAM12, compared to the control cells 
treated with 0, 0.5, 2, 8, 24, and 96 ng/ml exogenous hEGF for 10 or 30 minutes (Figure 3.3 a 
and b). Finally, no physical interaction was detected between ADAM12 and EGFR when co-
immunoprecipitation experiment was performed (Figure 3.3 c). Collectively, those results 
suggest that ADAM12 activates EGFR, most likely by mediating the release of endogenous 
EGFR ligands. 
 
Discussion 
EGFR plays an essential role in tumor progression in TNBC where ER, PR, and HER2 
are absent. Therefore, it is not surprising that 60-70% of the TNBCs show increased expression 
of EGFR (Corkery 2009; Shien 2005; Viale 2009). As a result, anti-EGFR therapies in TNBC 
have been tested in several clinical trials (Carey 2011). EGFR activation depends on ligands that 
are first synthesized as transmembrane precursors and need to be released from the surface of 
cells by ADAM sheddases (Kataoka 2009). Depending on the individual contribution of specific 
ADAMs to releasing EGFR ligands and modulating the activation of the EGFR signaling 
pathway, ADAMs might be promising targets in treatment of TNBC patients. ADAM12 is one of 
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the catalytically active ADAMs and its expression is strongly upregulated in breast cancer (Li 
2012; Fröhlich 2011; Roy 2011). Moreover, it has been shown that ADAM12 acts as a sheddase 
for HB-EGF, an EGFR ligand, during cardiac hypertrophy (Asakura 2002). Also, our RNA 
sequencing results showed that ADAM12 knock-down induces similar gene expression changes 
as inhibition of EGFR signaling (Duhachek-Muggy and Qi 2017). Thus, ADAM12 might play a 
critical role in the activation of EGFR in breast cancer cells. 
 In this report, we identified ADAM12 as a modulator of the EGFR pathway in 
SUM159PT TNBC cell line. We analyzed the basal level of pY1068, one of the major 
autophosphorylation sites in EGFR. The phosphorylation of Y1068 was increased when cells 
were treated with hEGF and decreased upon treating cells with erlotinib, which confirmed the 
functionality of the receptor and the specificity of the antibody. Also, we showed that the 
activation of EGFR in SUM159PT cells depends mainly on the endogenously expressed ligands 
that need to be cleaved from the cell surface by ADAM sheddases. The main purpose of this 
study was to investigate the role of ADAM12 in the activation of the EGFR pathway; knocking-
down ADAM12 decreased the basal activation level of EGFR, most likely by diminishing the 
release of EGFR ligands. 
In the scientific literature, ADAM10 and ADAM17 are considered to be the main 
sheddases releasing EGFR ligands in many cell types (Jones, Rustagi, & Dempsey 2016). In 
breast cancer, it has been postulated that ADAM17 is the main ADAM responsible for the 
cleavage of EGFR ligands and activating EGFR signaling (Giricz 2013). Our data indicates that 
ADAM12 is also capable of activating EGFR in breast cancer cells. This finding may have many 
important implications in developing a future treatment for TNBC. First, since TNBC is non-
responsive to anti-estrogen and anti-HER2 therapies, the only remaining the therapeutic option is 
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chemotherapy, which usually targets not only cancer cells but also normal dividing cells. 
Therefore, developing specific therapies that target ADAM12 to limit the release of EGFR 
ligands might serve as an alternative approach to treat TNBC patients. Second, knowing the 
major sheddases responsible for the high activity of EGFR in TNBC could help identify patients 
who might be the best candidates for anti-EGFR therapies. 
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Figure 3.1 The basal activation of EGFR in SUM159PT cells is mediated by endogenously 
expressed ligands. 
(a) Basal activation of EGFR in SUM159PT cells. Total cell lysates from untreated cells, 
cells treated for 24 hours with 1 µM erlotinib, an EGFR inhibitor, cells treated for 30 minutes 
with 20 ng/ml human recombinant EGF (hEGF), or both, were analyzed by Western blotting 
using anti-pY1068 EGFR, anti-EGFR and anti-MEK 1/2 antibodies. MEK 1/2 was used as a gel-
loading control. (b) The effect of BB-94 on the basal level of EGFR activation. SUM159PT cells 
were treated with 0, 10, or 50 µM of BB-94, a metalloprotease inhibitor, for 24 hours. Protein 
levels of pY1068 EGFR, EGFR and MEK 1/2 were analyzed by Western blotting. 
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Figure 3.2 ADAM12 knock-down decreases the basal activation of EGFR.  
(a) SUM159PT cells were transfected with a pool of four control siRNAs (siControl) or 
two different ADAM12 siRNAs (siA12 #1 and siA12 #2, respectively). Cells were incubated 
with either complete medium or serum-free medium for 24 hours before collecting total lysates 
72 hours after transfection. Representative blots are shown (n=2). (b) SUM159PT cells were 
transfected with a pool of four control siRNAs (siControl) and two different ADAM12 siRNAs 
(siA12 #1 and siA12 #2, respectively). Cells were either untreated or treated with 10 µM BB-94 
for 24 hours or with 20 ng/ml hEGF for 30 minutes before the analysis. 
 
 
 
 
pY1068	
EGFR	
MEK	1/2	
SUM159PT	
-Serum	 +Serum	
a	 b	
pY1068	
EGFR	
MEK	1/2	
DMSO	 10	μM	BB-94	 20	ng/ml	hEGF	
SUM159PT	
66 
a	
MCF10A.EV	 MCF10A.A12	
0	 0.5	 2	 8	 24	 96	
pY1068	
EGFR	
Tubulin	
0	 0.5	 2	 8	 24	 96	hEGF	concentra7on	
(ng/ml),	10	minutes	
hEGF	concentra7on	
(ng/ml),	30	minutes	
pY1068	
EGFR	
Tubulin	
b	
MCF10A.EV	 MCF10A.A12	
0	 0.5	 2	 8	 24	 96	 0	 0.5	 2	 8	 24	 96	
Lysis		
Buﬀer	
an7-A12	Ab		
control	IgG1		
															IP											
MCF10A.A12		
	
MCF10A.EV	
ADAM12	
ADAM12	
EGFR	
+	 _	 _	 +	 _	
_	 +	
_	 _	 +	 _	 _	 +	 _	
TL		 															IP											TL
c	
116	
97	
 
Figure 3.3 ADAM12 does not alter the EGFR responsiveness to EGF.  
 (a, b) EGFR response of MCF10A.A12 and MCF10A.EV cells to exogenous hEGF after 
10 (b) and 30 (c) minute treatment. MCF10A cells with stable over expression of ADAM12 or 
control empty vector (EV) were treated with the indicated doses of hEGF. Total cell lysates were 
analyzed by Western blotting using an antibody specific for pY1068 EGFR or total EGFR. 
Tubulin was used as a gel-loading control. (c) Lack of co-immunoprecipitation of ADAM12 and 
EGFR. MCF10A.A12 or MCF10A.EV cell lysates were incubated with anti-ADAM12 or control 
IgG1 antibody, and the immunoprecipitates were immunoblotted with antibodies against 
ADAM12 or EGFR. The band at 116 kDa represents the nascent, full-length and catalytically 
inactive form of ADAM12, the band at 97 kDa represents the mature, processed and catalytically 
active form of ADAM12. 
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Chapter 4- Final conclusions 
ADAMs function as sheddases when they are catalytically active (Edwards 2009; Seals & 
Courtneidge 2003; Mochizuki & Okada 2007). Sheddases are proteins that cleave ectodomains 
of specific transmembrane proteins, resulting in the release of their ectodomains to the 
surrounding space (Mochizuki & Okada 2007). These transmembrane proteins might be growth 
factor precursors, membrane-anchored ligands or receptors. The sheddase activity results in the 
activation or inhibition of various signaling pathways that might modulate specific cellular 
processes in the cell or might lead to or be associated with a particular pathological condition 
(Seals & Courtneidge 2003; Murphy 2008; Mochizuki & Okada 2007). In humans, twenty-two 
different ADAMs have been identified, and not all of the identified ADAMs are catalytically 
active. In addition, ADAMs show different patterns of expression, for example, one third of 
human ADAMs are expressed in the testis or its associated structures. Moreover, ADAM 
expression is upregulated in different pathological conditions (Edwards 2009; Reiss & Saftig 
2009). Among the identified human ADAMs, ADAM8, ADAM9, ADAM10, ADAM12, 
ADAM15, ADAM17, ADAM19, and ADAM28 are catalytically active (Jones, Rustagi, & 
Dempsey 2016; Reiss & Saftig 2009). ADAM17 is the most extensively studied ADAM since it 
has a wide variety of substrates. In breast cancer, it has been shown that ADAM12, ADAM17, 
and ADAM28 promote cancer cell proliferation by shedding different transmembrane proteins, 
such as HB-EGF (Mochizuki & Okada 2007; Jones, Rustagi, & Dempsey 2016). 
As mentioned previously, shedding of different transmembrane proteins has important 
consequences for many signaling pathways or biological processes. For example, activation of 
the EGFR signaling pathway depends on shedding its ligands, such as EGF, HB-EGF, and 
others, from the cell surface (Kataoka 2009). Moreover, SASP components that are expressed as 
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transmembrane proteins need to be shed from the cell surface to affect the neighboring cells 
(Coppé 2010; van Deursen 2014). ADAM metalloproteases are good candidates to modulate 
those processes. 
In chapter 2, the expression levels of catalytically active ADAMs, ADAM8, ADAM9, 
ADAM10, ADAM12, ADAM15, ADAM17, ADAM19, and ADAM28, were tested after 
induction of senescence in SUM102PT breast cancer cell line using TGFβ as an inducer of 
senescence. ADAM12 mRNA levels were significantly increased upon induction of cellular 
senescence. A future question that needs to be answered is: is ADAM12 protein also upregulated 
at the surface of senescent cells? If ADAM12 protein is upregulated, what is the function of 
ADAM12 in cellular senescence? Does ADAM12 regulate the cleavage of critical SASP 
components that might have an effect on the neighboring cells and, as a result, modulate tumor 
progression? Exploring the identities of SASP components that might require ADAM12 for 
cleavage is also important. The proteomic analyses could be used to answer this question, 
followed by performing knock-down experiments toward understanding the functional role of 
ADAM12. Modulating cell proliferation might be one of the functions of ADAM12, since we 
found in chapter 3 that ADAM12 activates EGFR signaling. Another interesting question that 
needs to be answered is whether ADAM12 expression is upregulated regardless of the approach 
that is used to induce cellular senescence. If the answer is yes, could ADAM12-targeting therapy 
provide a valuable approach to control the release of SASP components that increase tumor 
growth and progression of cancer? Induction of cellular senescence by different approaches and 
testing ADAM12 expression is a good strategy to answer those questions. 
Another important observation in chapter 2 is that ADAM17 mRNA expression did not 
increase upon induction of cellular senescence, however, this does not exclude the possibility 
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that ADAM17 protein expression or its activity is increased. Effenberger et al showed that 
ADAM17 activity, but not its protein level, increased upon induction of cellular senescence 
(Effenberger 2014); this could be the case in TGFβ-induced senescence as well.   
Finally, ADAM28 expression was upregulated upon induction of cellular senescence. 
Previously, ADAM28 was found to be upregulated in breast cancer cells (Mitsui 2006). It would 
be interesting to study the effect of combined knock-down of ADAM12 and ADAM28 on SASP.  
In chapter 3, we showed that ADAM12 modulates EGFR activation. These results were a 
part of a bigger study that showed that ADAM12-mediated activation of EGFR leads to 
enrichment for cancer stem cells (CSCs) populations. CSCs are resistant to cancer therapies and 
play important roles during metastasis (Ghaffari 2011). Inhibition of ADAM12 might in the 
future represent an anti-CSC therapy, as well as an approach to diminish SASP. 
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